4-(3-phenyl-propyl)-benzoic acid | 6337-66-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 4-(3-phenyl-propyl)-benzoic acid
• 英文别名: 4-(3-Phenyl-propyl)-benzoesaeure；4-(3-Phenylpropyl)-benzoic Acid；4-(3-phenylpropyl)benzoic acid
• CAS: 6337-66-2
• 化学式: C₁₆H₁₆O₂
• 分子量: 240.302
• InChiKey: LUCNGOVVTMVUGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(3-phenyl-propyl)-benzoic acid 在 三氯化铝 、 氯化亚砜 作用下， 以 二硫化碳 为溶剂， 反应 9.0h， 生成
  参考文献：
  名称：

  Photochemistry of bichromophoric aromatic diketones: the effect of methylene chain

  摘要：

  DOI：

  10.1021/jo00263a051
• 作为产物：
  描述：

  1,3-二苯丙烷 在 三氯化铝 、 potassium hypochlorite 作用下， 生成 4-(3-phenyl-propyl)-benzoic acid
  参考文献：
  名称：

  Macro Rings. IV. The Preparation of Three New Paracyclophanes¹

  摘要：

  DOI：

  10.1021/ja01638a022

文献信息

• Inhibitors of histone deacetylase
  申请人：MethylGene, Inc.

  公开号：US06541661B1

  公开（公告）日：2003-04-01

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  这项发明涉及抑制组蛋白去乙酰化酶。该发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DEACETYLASE
  申请人：METHYLGENE INC

  公开号：WO2004035525A1

  公开（公告）日：2004-04-29

  The invention provides compoods and methods for treating cell proliferative- diseases. The invention provides new inhibitors of histone deacetylase enzymatic activity, compositions of the compounds comprising the inhibitors and a pharmaceutically acceptable carrier, excipient, or diluent, and methods of using the compounds to inhibit cellular proliferation in vitro and therapeutically.

  这项发明提供了用于治疗细胞增殖性疾病的化合物和方法。该发明提供了新的组织脱乙酰酶酶活性抑制剂，包括这些抑制剂的化合物组合物和药学上可接受的载体、赋形剂或稀释剂，以及使用这些化合物在体外和治疗上抑制细胞增殖的方法。
• Carboxylic acid derivatives as IP antagonists
  申请人：——

  公开号：US20010056100A1

  公开（公告）日：2001-12-27

  This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: 1 wherein: R 1 , R 2 , and R 3 are each independently in each occurrence aryl or heteroaryl; R 4 is —COOH or tetrazolyl; A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and processes for their preparation.

  这项发明涉及一类通常为IP受体拮抗剂的化合物，其由以下式I表示： 其中： R1、R2和R3在每次出现时各自独立地为芳基或杂环芳基； R4为—COOH或四唑基； A、B、m、n和r如规范中定义； 或其各个异构体、外消旋或非外消旋异构体混合物，或其药用可接受盐或溶剂合物。该发明还涉及含有这种化合物的药物组合物，以及将其用作治疗剂的方法和其制备方法。
• Unnatural Polyketide Analogues Selectively Target the HER Signaling Pathway in Human Breast Cancer Cells
  作者：Seok Joon Kwon、Moon Il Kim、Bosung Ku、Lydie Coulombel、Jin-Hwan Kim、Joseph H. Shawky、Robert J. Linhardt、Jonathan S. Dordick

  DOI：10.1002/cbic.200900674

  日期：2010.3.1

  Multiple HER TK inhibitor: In vitro precursor‐directed syntheses of polyketide analogues resulted in the identification of several “unnatural” natural products that suppressed the HER‐PI3K‐Akt signaling pathway, as well as having multiple HER TK inhibitory activity.

  多种 HER TK 抑制剂：聚酮化合物类似物的体外前体定向合成导致鉴定了几种抑制 HER-PI3K-Akt 信号通路以及具有多种 HER TK 抑制活性的“非天然”天然产物。
• [EN] CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS<br/>[FR] DERIVES D'ACIDE CARBOXYLIQUE UTILISES COMME DES ANTAGONISTES D'IP
  申请人：HOFFMANN LA ROCHE

  公开号：WO2001068591A1

  公开（公告）日：2001-09-20

  This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula (I) wherein R?1, R2, and R3¿ are each independently in each occurrence aryl or heteroaryl, R4 is -COOH or tetrazolyl, A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, processes for their preparation and their use as therapeutic agents.

  本发明涉及一类化合物，通常为IP受体拮抗剂，其由式（I）表示，其中R1、R2和R3在每次出现时均独立地为芳基或杂环芳基，R4为-COOH或四唑基，A、B、m、n和r如规范中所定义；或其各个异构体，混合物，或其药学上可接受的盐或溶剂。本发明还涉及含有这种化合物的药物组合物，其制备方法以及作为治疗剂的用途。